Predicting relapse and infection to optimize patient outcomes in ANCA-associated vasculitis: data from the MAINRITSAN trials cohort

Clicks: 27
ID: 330018
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #29 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Long-term follow-up of the MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV). Extending RTX maintenance beyond 18 months may benefit high-risk patients. The aim of this study was to validate relapse and infection prediction models to guide individualized RTX extension decisions. METHODS: Data from 217 patients in the MAINRITSAN1 and MAINRITSAN2 trials treated with RTX for 18 months with follow-up through December 2020 were analyzed. We externally validated relapse and infection prediction models from McClure et al. Primary endpoints were relapse-free survival and serious infection-free survival. RESULTS: Relapse occurred in 76 patients, with a 72-month relapse-free survival rate of 55% (95% CI 48-64). Serious infections occurred in 33 patients, with a cumulative 72-month incidence of 20%. The relapse model (factors: male sex, age > 60 years, ANCA positivity, relapsing disease, ENT involvement, prednisone dose) predicted major relapse (coefficient 1.34, p = 0.04) and identified high-risk patients with shorter major relapse-free survival (HR 1.91, 95% CI 0.97-3.76, p = 0.059). The relapse score was associated with major relapse risk predominantly within the PR3-ANCA subgroup (coefficient 2.76, p = 0.01). The infection model (factors: male sex, structural lung disease, diabetes, occurrence of infections during maintenance therapy, and gammaglobulin level) identified high-risk patients with shorter serious infection-free survival (HR 2.93, 95% CI 1.28-6.72, p = 0.011). CONCLUSION: The relapse prediction model demonstrated reproducible performance in this external validation cohort and may contribute to clinically relevant risk stratification, especially in PR3-ANCA patients. The infection model showed stronger predictive performance and may support individualized discussions regarding RTX extension.
Reference Key
openalex_W7214683036 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Florence Delestre, Pierre Charles, Maxime Samson, N. Antoine, Stanislas Faguer, Alexandre Karras, François Lifermann, Pascal Godmer, Catherine Hanrotel‐Saliou, N. M. Silva, Grégory Pugnet, François Maurier, Thomas Le Gallou, Thomas Quéméneur, Nadine Méaux-Ruault, Jean-Francois Viallard, Eric Hachulla, Xavier Puéchal, Loïc Guillevin, Raphael Porcher, Benjamin Terrier, the French Vasculitis Study Group (Fvsg), Christian Agard, Julien Allard, Jean-Benoit Arlet, D. Bagnères, Edouard Bégon, Anne-Bérangère Beucher, Claire Blanchard‐Delaunay, Frédéric Bocquentin, Anthony Bonnin, Ali Boumallassa, B. Brihaye, Mathias Buchler, Sébastien Canet, Richard Damade, I de Lacroix-Szmania, Christian Delafosse, Sébastien Delbès, Xavier Delbrel, Mathilde de Menthon, Claire de Moreuil, Robin Dhôte, Bertrand Dunogué, Cécile-Audrey Durel, Marc Fabre, Olivier Fain, Hélène Francois, Marie Frimat, Jean-Michel Galempoix, Helder Gil, Bernard Gilson, G. Gondran, F. Grassin, Isabelle Guichard, Constance Guillaud, H. Kassem, Abdeldjallil Koreichi, X. Kyndt, L. Lahaxe, Nathalie Lerolle, Guillaume Leveiller, Olivier Lidove, Marie Lino-Daniel, Roderich Meckenstock, Stéphanie Mestrallet, Luc Mouthon, Thomas Papo, Romain Paule, Simona Pavel, Laurent Perard, Serge Perrot, Vincent Poindron, Mathieu Puyade, Nolwenn Rabot, Alain Ramassamy, Alexis Régent, Claire Rigothier, Sophie Rivière, Raphaele Seror, Aurélie Schiffman, N. Schleinitz, D. Sène, Audrey Sultan, N. Tieulié, Christine Vinter, Stephane Vinzio, Ursula Warzocha, L Wemeau
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag542
URL
https://doi.org/10.1093/rheumatology/keag542
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.